Insmed announced it will present six abstracts at the American Thoracic Society International Conference 2026, including new data on ARIKAYCE for Mycobacterium avium complex lung disease and BRINSUPRI for non-cystic fibrosis bronchiectasis. The company also shared pharmacokinetic findings on investigational treprostinil palmitil inhalation powder and highlighted disease burden in pulmonary hypertension. Additionally, Insmed is funding a research grant to improve bronchiectasis diagnosis across the U.S., aiming to reduce misdiagnosis and enhance patient care. These efforts underscore Insmed's commitment to advancing treatments for serious respiratory diseases.
Ferrari has launched the Luce, its first fully electric vehicle, priced above $586,000 and capable of reaching 193 mph. This four-door EV marks a major shift for the brand, which aims to maintain its iconic status without the traditional combustion e...
The global aerospace materials market is projected to grow from $60.38 billion in 2026 to $89.58 billion by 2031, at a CAGR of 8.21%. Growth is fueled by rising demand for lightweight composite materials that improve fuel efficiency, increased satell...
State Street Global Advisors & Affiliates disclosed a sale of 1,250 ordinary shares of DCC plc on May 22, 2026, at a price of €61.55 per share. Following this transaction, their total holding in DCC plc stands at 1,189,951 shares, representing 1.3929...
NevGold Corp. reported that all 17 drillholes at its Limousine Butte project in Nevada returned consistent oxide antimony and gold mineralization, with notable grades such as 0.32% antimony over 14.9 meters. This brownfield site contains historic cru...
XRP has underperformed Bitcoin since 2017, with no signs of recovery, as highlighted by a UK-based technical analyst. Over the past three months, Bitcoin surged from around $60,000 to $80,000, while XRP traded mostly sideways near $1.36, losing key m...
